Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Peking University International Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04047576
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, Beijing, China
Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT03987152
- Locations
- 🇳🇱
Radboudumc, HECOVAN workgroup, Nijmegen, Gelderland, Netherlands
Optimizing PTCy Dose and Timing
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 400
- Registration Number
- NCT03983850
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- Radiation: Total-Body IrradiationDrug: ThiotepaDrug: FludarabineDrug: CyclophosphamideBiological: Peripheral Blood Stem CellDrug: TacrolimusBiological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCsDrug: MethotrexateDrug: CyclosporineDrug: BusulfanDrug: SirolimusProcedure: Bone Marrow Aspiration and BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Biospecimen Collection
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03970096
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
- Conditions
- Interventions
- Biological: AAV9-GLB1Procedure: Abdominal ultrasoundDrug: RituximabDrug: SirolimusDrug: MethylprednisoloneDrug: PrednisoneDiagnostic Test: Audiology assessment with ABRDiagnostic Test: Bone density scan (DEXA)Diagnostic Test: Electrocardiogram (EKG)Diagnostic Test: EchocardiogramOther: Electroencephalogram (EEG) awake and extended overnightDiagnostic Test: Laboratory testsProcedure: Lumbar punctureProcedure: Brain MRI/MRS/fMRIBehavioral: Neurocognitive testingOther: Neurology examBehavioral: PICC or other Central line placementProcedure: Skeletal surveyProcedure: Skin biopsyProcedure: Speech and modified barium swallow studyProcedure: Ophthalmology exam
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Target Recruit Count
- 45
- Registration Number
- NCT03952637
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
The Efficacy and Safety of Sirolimus for Plastic Bronchitis
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03942926
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 24
- Registration Number
- NCT03933904
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 30
- Registration Number
- NCT03910452
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03866681
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.